XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SEGMENTS
 6 Months Ended
Jun. 30, 2024
SEGMENTS [Abstract]  
SEGMENTS
11.
SEGMENTS


The Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics.  The Company’s ADMA BioManufacturing operating segment reflects the Company’s immunoglobulin manufacturing, commercial and development operations in Boca Raton, FL.  The Plasma Collection Centers operating segment consists of  ten plasma collection facilities located throughout the United States, all of which are operational, collecting plasma and currently hold FDA licenses. The Company defines its operating segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to analyze performance and allocate resources. While not considered an operating segment, the Corporate information included in the tables below consists of certain unallocated general and administrative overhead expenses and interest expense on the Company’s senior debt (see Note 7). The Company’s CODM is its President and Chief Executive Officer. For the Company’s two operating segments, the CODM uses income/loss before taxes as the measure of segment profit to determine the allocation of resources for each segment. Summarized financial information concerning reportable segments is shown in the following tables:

Three Months Ended June 30, 2024
  
    ADMA    
Plasma Collection
             
(in thousands)  
BioManufacturing
    
Centers
    
Corporate
    
Consolidated
  
                         
Revenues
  
$
106,183
    
$
972
    
$
36
    
$
107,191
  
                                 
Cost of product revenue
    
48,471
      
1,267
      
-
      
49,738
  
                                 
Income (loss) from operations
    
46,712
      
(1,237
)
    
(6,274
)
    
39,201
  
                                 
Interest and other expense, net
    
(10
)
    
(3
)
    
(3,337
)
    
(3,350
)
                                 
Income (loss) before taxes
    
46,702
      
(1,240
)
    
(9,611
)
    
35,851
  

                               
Depreciation and amortization expense
   
1,241
      
806
      
-
      
2,047
  
Total assets
     258,095       33,607       84,697       376,399  

Three Months Ended June 30, 2023
  
    ADMA    
Plasma Collection
             
(in thousands)  
BioManufacturing
    
Centers
    
Corporate
    
Consolidated
  
                         
Revenues
  
$
59,761
    
$
326
    
$
36
    
$
60,123
  
                                 
Cost of product revenue
    
43,041
      
392
      
-
      
43,433
  
                                 
Income (loss) from operations
    
6,084
      
(1,400
)
    
(5,157
)
    
(473
)
                                 
Interest and other (expense) income, net
    
(6
)
    
1
      
(5,893
)
    
(5,898
)
                                 
Income (loss) before taxes
    
6,078
      
(1,399
)
    
(11,050
)
    
(6,371
)
                                 
Total assets
    
248,163
      
37,459
      
57,405
      
343,027
  
Depreciation and amortization expense
    1,283       815       -       2,098  

Six Months Ended June 30, 2024
  
    ADMA    
Plasma Collection
             
(in thousands)  
BioManufacturing
    
Centers
    
Corporate
    
Consolidated
  
                         
Revenues
  
$
186,297
    
$
2,698
    
$
71
    
$
189,066
  
                                 
Cost of product revenue
     89,462
      
3,043
      
-
      
92,505
  
                                 
Income (loss) from operations
     75,409      
(2,292
)
    
(12,095
)
    
61,022
  
                                 
Interest and other expense, net
     (41 )    
(4
)
    
(6,725
)
    
(6,770
)
                                 
Income (loss) before taxes
    
75,368
      
(2,296
)
    
(18,820
)
    
54,252
  
                                 
Capital expenditures
     4,338       75       -       4,413  
Depreciation and amortization expense
    
2,548
      
1,613
      
-
      
4,161
  

Six Months Ended June 30, 2023
  
    ADMA    
Plasma Collection
             
(in thousands)  
BioManufacturing
    
Centers
    
Corporate
    
Consolidated
  
                         
Revenues
  
$
109,339
    
$
7,627
    
$
71
    
$
117,037
  
                                 
Cost of product revenue
    
76,975
      
6,859
      
-
      
83,834
  
                                 
Income (loss) from operations
    
11,561
      
(2,346
)
    
(10,501
)
    
(1,286
)
                                 
Interest and other expense, net
    
(30
)
    
-
      
(11,844
)
    
(11,874
)
                                 
Income (loss) before taxes
    
11,531
      
(2,346
)
    
(22,345
)
    
(13,160
)
                                 
Capital expenditures
     1,195       1,622       -       2,817  
Depreciation and amortization expense
    
2,575
      
1,556
      
-
      
4,131
  

Net revenues according to geographic area, based on the location of where the product is shipped, is as follows:
   
Three Months Ended June 30,
    
Six Months Ended June 30,
  
(in thousands)  
2024
   
2023
   
2024
   
2023
 
United States
  
$
102,726
    
$
56,608
    
$
180,717
    
$
109,303
  
International
    
4,465
      
3,515
      
8,349
      
7,734
  
Total revenues
  
$
107,191
    
$
60,123
    
$
189,066
    
$
117,037